FDA approves Dupixent for chronic obstructive pulmonary disease
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) Friday said the National Medical Products Administration (NMPA) in China has
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).The drug,
FDA Approves Dupixent for Some Patients Struggling With COPD Symptoms
Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain patients with COPD. Read more here.
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.
Managed Healthcare Executive10h
Breakthrough Blood Test Could Predict Rapid Lung Decline
A rapid decline in lung function is linked to the development of chronic obstructive pulmonary disease (COPD) ...
TheHealthSite7y
Chronic Obstructive Pulmonary Disease
Chronic Pulmonary Obstructive Disease: What are its symptoms and causes and why is it important to quit smoking in the current season. Some people suffer from Asthma and COPD simultaneously ...
Hosted on MSN2mon
Chronic obstructive pulmonary disease (COPD): Signs to watch out for
Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing ...
framinghamsource4d
New Pulmonary Rehabilitation Program at MetroWest Medical Center is a Breath of Fresh Air for Those with Chronic Lung Disease
For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...
Yahoo Finance21d
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast to 2033: Focus on US, France, Germany, Italy, Spain, UK, and Japan
Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease (COPD): Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. In the ...
Medscape4d
High Dose N--Acetylcysteine in Patients With Exacerbations of Chronic Obstructive Pulmonary Disease
Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).